Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing - Wikidata - awgldk - TriplyDB

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

http://www.wikidata.org/entity/Q34029615

about

EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.Genetic-based prediction of disease traits: prediction is very difficult, especially about the future Whole genome sequencing for lung cancer.Colorectal cancer in iran: molecular epidemiology and screening strategies.Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran.A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma.Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics.Diagnostic RAS mutation analysis by polymerase chain reaction (PCR).Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis.Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations.Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort.Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie What makes oncogenes mutually exclusive?Challenges of development and implementation of point of care pharmacogenetic testing.KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.A novel KRAS gene mutation report in sporadic colorectal cancer, from Northwest of Iran.Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.

P2860

Q26853071-CE2723C6-2C7D-4D44-BEFB-03308D589F75 Q28384015-667EBD9A-36C2-4A1A-B1EE-2B1559417E92 Q33405398-79346165-905A-489B-AEB4-E56DD66530FC Q33693846-7F550AC1-AC78-4574-9E76-0B0919DC46CD Q34352229-AE9E83EB-81CE-444E-B845-2065C8C181B3 Q35034089-62926F4B-E6AD-47ED-B3B6-ECBB41CC540B Q35663416-A25E3B62-2E49-42AB-AFAE-3DE86205C752 Q36166765-CD76D6DB-D577-43D1-BEB2-F5FDC2E9DB9F Q36229011-97B546B6-84C9-495E-999B-8584AB2CBF54 Q36523724-5E40A75A-5E2F-4C1C-8E46-E2D6FBEEDA3B Q36582552-3295DF9F-B67F-42FE-BB10-84300E462FB8 Q36667504-927DF0D4-667E-412A-85D2-302902B5159D Q36790406-B1AE640E-6382-402B-A99A-22B7ACF0D0E0 Q36830260-179EE040-55CA-4996-975E-A431CB04F79E Q37000019-87759F80-914A-4B24-9035-B3C886A56924 Q37038806-737FB2BE-ABE5-44AE-9930-B87888A0B437 Q37110456-8F1112BB-339F-471D-B420-E8EA8752E1D4 Q37601544-361F8B04-2962-4325-8458-DE309DF83D54 Q37653893-A8FF95C2-D12D-4FD6-8C94-25208E8B0265 Q38061599-6A39957D-1FE9-401B-9F67-8C1B796BE048 Q38136134-D9C3A89A-C021-4A27-856C-A288ECE54618 Q38853649-1424C774-5BBD-4F37-A940-91AA2F8B9574 Q38924458-B3C4C720-AE5F-44E2-B7AC-FC21F79E582B Q39065326-05CC003E-79C2-4094-9B33-2A4EC3A874C7 Q39172118-97414148-9527-4AED-8CB2-ADA1ECA26E00 Q39602248-A06A8A14-179F-4F26-901A-8645DE5A94FA Q39611892-F5C2ED9A-EDA5-4A77-BD1A-CE7A5A889497 Q40108385-58F18174-5A4C-4FF5-956E-1A02CFBE0BF7 Q40364772-D5AAC9D4-1E4E-494E-9072-A8B265895F6B Q40885761-6D0E2997-9905-49CB-8E57-7CEFC6A444BD Q42319173-A5804035-2E8C-46AF-83AA-B25ED31F59A2 Q44695743-1538967F-D9E5-41A9-A619-B273F1688792 Q50738801-D5C7BDEB-1450-4F16-BDD9-A5F8E45707BF Q52332839-7F01E5FA-F51B-4159-A5E3-5571D22D9FC0 Q53335041-0F4C7F20-7370-4683-954F-9C6BA8089232

P2860

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

http://www.wikidata.org/entity/Q34029615

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@ast

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@en

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@nl

type

label

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@ast

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@en

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@nl

prefLabel

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@ast

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@en

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@nl

P1433

Q34029615-4B11E343-9553-42E8-8328-299E92A4F646

P1476

Q34029615-943B3817-FAC0-47CB-8713-AC1ED14BCBAE

P2093

Q34029615-1FDE2426-57B6-4655-BDC8-C3B0E55A74F4

Q34029615-3C67DE7B-3C19-4344-9DD1-F898317508B1

Q34029615-3E10F11D-B90C-4C4F-A31B-6ABB9F4294D4

Q34029615-5623B13B-3384-452F-BD64-AC9ABA459983

Q34029615-63B60693-0356-4788-B1B4-088B500DBB59

Q34029615-900A25E7-A910-4EB6-AA8B-227AB122C2F7

Q34029615-96B04FDA-8F6F-4409-A1EE-1696F58B7F18

Q34029615-9B8F60DF-5546-4233-801C-5A3A621EA933

Q34029615-A8258CC7-88F5-4696-BCD5-F79C81B85AF7

Q34029615-E9358876-BE76-4CFB-9261-30ABF67D11AE

P2860

Q34029615-0CF44B19-6483-4009-8789-9457E4F08657

Q34029615-104F9F13-F4DA-41B3-97ED-38A3408CB151

Q34029615-15D9D5A5-8203-4667-B6A3-04DD91D178F1

Q34029615-23185723-C7BC-48C9-B6BF-E76BDAB15B3D

Q34029615-25318F02-B802-4613-9550-6B010B1C20D9

Q34029615-28D19523-8E04-4EDD-B089-A92F5E875BE5

Q34029615-3E267148-830F-4914-BAE2-5CF5BC92F623

Q34029615-4318D5F3-2D64-4EF2-A8CB-5A1A31BFE206

Q34029615-5BD8E220-1E92-4CC2-9B0A-1A1C9C88B52A

Q34029615-65A76861-03F8-4E95-A1A4-0B4043417469

P2888

Q34029615-85D7B5F9-166F-4C07-B20F-A91DC7201D1A

P304

Q34029615-916C9006-0C35-4DE0-BDB8-645D59E5FE32

P31

Q34029615-7C19E033-D7B4-47C1-A764-0C8D891E4DA6

P356

Q34029615-F3B801D2-FDA3-4EB0-962B-F8B9C6816DAC

P407

Q34029615-B7ADD378-A207-498E-9F15-A7A891A71AB1

P478

Q34029615-6AF05645-10C4-43E1-AC8B-EC02433A9E50

P50

Q34029615-FF4D7CB2-61C7-4452-9071-03CF797272F1

P577

Q34029615-0D731871-BBCF-4F09-8D1C-330423F80418

P5875

Q34029615-49417B47-225A-4C78-B701-6F7B39FF8A67

P6179

Q34029615-3A4230C5-F759-443B-8FAC-5730839D2AE6

P698

Q34029615-6BD4B341-888B-45E6-BD6D-94E4BF44CA90

P921

Q34029615-484CAA42-BEE4-4EA3-B64B-F51C878350CB

P932

Q34029615-5199D9A8-CDBE-451B-8A98-62DA6E0A6AEE

P356

1471-2407-11-406

P1433

P1476

Clinical pharmacogenomic testi ...... and ultra-deep pyrosequencing

@en

P2093

Angels Arcusa

http://www.w3.org/2001/XMLSchema#string

Begoña Mañé

http://www.w3.org/2001/XMLSchema#string

Emma Borràs

http://www.w3.org/2001/XMLSchema#string

Imma Hernan

http://www.w3.org/2001/XMLSchema#string

Isabel Martí

http://www.w3.org/2001/XMLSchema#string

Ismael Jurado

http://www.w3.org/2001/XMLSchema#string

María José Gamundi

http://www.w3.org/2001/XMLSchema#string

Miguel Blanca

http://www.w3.org/2001/XMLSchema#string

Miguel Carballo

http://www.w3.org/2001/XMLSchema#string

Miguel Dias

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

ras oncogenes in human cancer: a review

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Screening for epidermal growth factor receptor mutations in lung cancer

P2888

1471-2407-11-406

P304

406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-406

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51670520

http://www.w3.org/2001/XMLSchema#string

P6179

1013753802

http://www.w3.org/2001/XMLSchema#string

P698

21943394

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

3192787

http://www.w3.org/2001/XMLSchema#string